-
Private label, Bayer drive down internal analgesics
Internal analgesics is slightly down in retail sales with a 0.6% decrease year-over-year. As the largest segment in internal analgesics, tablets were down 0.4%. This performance was driven down primarily by private label and Bayer products. Private-label internal analgesics were down 5%, and Bayer was down 4%. Pfizer saw no change in sales. McNeil’s return to the market did well, reflecting a 17% increase over the same time period last year. The external analgesic category was up 7% year-over-year.
-
Migraine may be next switch
The next big Rx-to-OTC switch opportunity in 2017 could be migraine treatments.
(To view the full Category Review, click here.)
“They did switch Imitrex [in Europe],” Laura Mahecha, industry manager healthcare for Kline Group, said, citing concerns of “potential cardiovascular side effects.” Mahecha called the potential of a 2017 migraine switch “low to moderate.”